Axel Johnson advances social impact investing initiative with investment in Neopenda.
On February 25th, Axel Johnson closed on a seed investment in Neopenda PBC, a start-up medical device company innovating technologies to improve health outcomes in emerging markets. Their first product targets reducing infant mortality globally. Advancing newborn health and reducing preventable deaths is a goal that has attracted the attention of the UN and the WHO, and substantive progress will require innovative and cost-effective medical technologies. Neopenda is developing a comprehensive infant vital signs monitor that is tailored to developing countries, where 98% of the deaths of infants younger than one month occur. Their first product, a battery-powered and bluetooth-enabled vital signs monitor, is designed for resource-constrained health facilities where power supply and working WiFi are not reliable. The affordable system enables more responsive and appropriate care for critically ill newborns, and ultimately helps reduce preventable newborn mortality.
Axel Johnson strongly believes in the mission of improving newborn health on a global scale and is partnering with Neopenda to support the final product development and commercialization of their vital signs monitor.
Neopenda is led by Sona Shah (CEO) and Teresa Cauvel (CTO), who founded the company while completing their Master’s degrees in Biomedical Engineering at Columbia University. Since its inception, Neopenda has received many accolades including selection and participation in Techstars Chicago 2018, MIT Solve Challenge 2018, and 2017 Women in Bio- Chicago Start-up Challenge while also being named to Business Insider’s 30 Under 40 Healthcare Leaders. As a social enterprise, Neopenda plans to reinvest most of their profits to achieve sustainability, grow their reach, and ensure the fulfillment of their mission. Axel Johnson is excited to support Neopenda’s growth and vision.
We would love to hear your company’s story and share our own.Contact Us